Sally has a Masters of Research in Neuropharmacology from Nottingham Trent. It was here where she discovered her love for cell signalling and neurodegenerative disease. Since then, Sally has been working on therapeutic applications for disease In Vitro. She has joined Neuro-Bio as a Research Scientist with a primary focus on cell culture as part of the Drug Discovery team.
Dr Sneha Anand
Sneha has a PhD in mammalian genetics and a Master’s degree in Biotechnology. On completing postdoctoral positions at the Medical Research Council, Sneha went on to pursue a career in translational medicine at the University of Oxford where her research was focused identifying blood-based proteomics biomarkers of Alzheimer’s disease. She has also gained significant industrial experience in successfully developing assays to be tested in the Phase I clinical trials.
Dr Giovanni Ferrati
Lead, Drug Discovery
Giovanni has a master in Neurobiology from the University of Turin in Italy, this was awarded with academic distinction. Additionally, he also has a bachelor in biotechnology from the university of Florence in Italy.
Daniel García Rodríguez
Daniel recently finished his 4-year degree in Biology from the University of Murcia (Spain). His neuroscience interest has allowed him to develop his skillset in organisations like the Biomedical Research Institute in Murcia (IMIB). Currently, under the ERASMUS scheme, he is working in the Drug discovery team and hopes that this internship will increase his knowledge in Neurobiology
Owen has an MSc in Molecular Neuroscience from the University of Bristol and a BSc in Biological Sciences from the University of Birmingham. He is currently working as part of the biomarker development team.
Matthew has an MBio in Biochemistry from the University of Warwick. After completing a year in industry with the company as an intern, he was given the opportunity to stay on at Neuro-Bio as a Research Scientist. Currently, his work is targeted towards the development of immunoassays which are used to detect a novel biomarker of Alzheimer’s disease.
Banu has a master’s degree in Diagnostic Microbiology from Istanbul University, Cerrahpasa Medical School in Istanbul. She has previously worked at Oxford University at the John Radcliffe Hospital in Microbiology Department as a Specialist Biomedical Scientist. During her career, she discovered a growing interest in quality control practices within the hospital. Eventually, she left the clinical hospital for the private sector where she worked as QC Laboratory Supervisor. She hopes that her experience gained throughout her career will benefit the Scientific and Management team here at Neuro-Bio.
Dr Henry Tu
Henry graduated in Biomedical and Pharmaceutical from the University of Reading. His research focuses on the neurodegenerative mechanism of Alzheimer’s disease (AD); this led him to joining Neuro-Bio Ltd as a Postdoctoral researcher, exploring novel approaches to neurodegeneration. In his new role as Principal Scientist, his main responsibilities include the development of an AD diagnosis and prognosis assay, sourcing biospecimen samples from biobanks around the world and line managing research scientists.
Eliz is completing an MBio in Biomedical Science from The University of Warwick, where she will be completing a year with the company as an intern. Her keen interest in neuropathology is what drove her to Neuro-Bio. She is currently a part of the biomarker development team and is assisting with developing the biomarker inter-assay sensitivity.
Culham Science Centre
Culham Science Centre
(+44) 01235 420085
© All Rights Reserved NeuroBio